From our own clinical experience in early-stage melanoma, TLR9 ligands like CpG-B oligodeoxynucleotides may be attractive candidates to include in such approaches as we showed local treatment with these compounds to induce strong recruitment and activation of the LNR-cDC and pDC subsets in SLN [49] and significantly improved recurrence-free survival [50]. This evidence concerns the gene TLR9 and melanoma.